^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HJ-N-001

    i
    Associations
    News

    Trials

    Company:
    Tianjin Hengjia Biotech
    Drug class:
    T-cell stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer (NCT04397926)
    Phase 1
    Sun Yat-sen University
    Recruiting
    Last update posted :
    06/12/2020
    Initiation :
    05/30/2020
    Primary completion :
    05/30/2022
    Completion :
    12/30/2022
    TNFRSF9
    |
    EGFR mutation
    |
    HJ-N-001